Although striatal delivery of three critical genes for dopamine synthesis by viruses is a
potential clinical approach for treating Parkinson's disease (PD), the approach makes it …

Introduction: Human pluripotent stem cells have the potential to differentiate into different cell
lineages of the human body, including dopaminergic (DA) neurons. Previous studies have …

Parkinson's disease (PD) is one of the most common neurodegenerative diseases caused
by specific degeneration and loss of dopamine neurons in substantia nigra of the midbrain …

One of the prospects for a curative treatment for Parkinson's disease is to replace the lost
dopaminergic neurons. Preclinical and clinical trials have demonstrated that dissected fetal …

Stem cell replacement has emerged as the novel therapeutic strategy for Parkinson's
disease (PD). Control of motor behavior is lost in PD due to the selective degeneration of …

Clinical studies involving intrastriatal transplantation of embryonic mesencephalic tissue in
patients with Parkinson disease (PD) have provided proof-of-principle for the cell …

Autologous dopamine (DA) neurons are a new cell source for replacement therapy of
Parkinson's disease (PD). In this study, we tested the safety and efficacy of autologous …

Cell-replacement therapies have long been an attractive prospect for treating Parkinson
disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with …

Parkinson's disease (PD) is the second most common neurodegenerative disease
worldwide, classically characterized by a triad of motor features: bradykinesia, rigidity and …

Parkinson's disease (PD) is currently the fastest growing disabling neurological disorder
worldwide, with motor and non-motor symptoms being its main clinical manifestations. The …